中国寄生虫学与寄生虫病杂志 ›› 2008, Vol. 26 ›› Issue (5): 2-331.

• 论著 • 上一篇    下一篇

伯氏疟原虫红内期融合抗原的构建、表达及其免疫原性研究

曹毅,张冬梅,潘卫庆*   

  1. 第二军医大学病原生物学教研室,上海 200433
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2008-10-31 发布日期:2008-10-31
  • 通讯作者: 潘卫庆

Construction and Expression of Plasmodium berghei Chimeric Protein in Pichia pastoris and its Immunogenicity in Mice

CAO Yi,ZHANG Dong-mei,PAN Wei-qing*   

  1. Department of Pathogen Biology,the Second Military Medical University,Shanghai 200433,China
  • Received:1900-01-01 Revised:1900-01-01 Online:2008-10-31 Published:2008-10-31
  • Contact: PAN Wei-qing

摘要: 目的 合成伯氏疟原虫红内期融合抗原基因PbCP-2.9,在毕赤酵母真核系统中表达其产物,并进行免疫原性分析。 方法 选取与恶性疟原虫红内期融合抗原基因PfCP-2.9具有同源性的伯氏疟原虫AMA1(Ⅲ)和MSP1-19序列,融合形成PbCP-2.9基因。基因序列经密码子优化,在毕赤酵母中分泌表达。60只BABL/c小鼠均分为6组,其中蛋白免疫组3组,分别用PbCP-2.9蛋白与福氏佐剂、ISA206和IMS1312佐剂乳化后,皮下注射免疫小鼠,抗原免疫剂量20 μg/只·次,注射体积200 μl,共免疫3次,每次间隔2周。佐剂对照组3组,以 PBS代替免疫抗原同法免疫。免疫前及每次免疫后1周鼠尾取血,分离血清。用ELISA和IFAT方法检测血清中特异性抗体的滴度及其与天然抗原的反应结果。 结果 PbCP-2.9基因在毕赤酵母中分泌表达出Mr约26 400的 PbCP-2.9蛋白,其与抗伯氏疟原虫红内期原虫的血清能进行特异性反应;ELISA检测PbCP-2.9蛋白免疫组结果表明,福氏佐剂组第2次免疫后特异性抗体滴度为(52.62±11.26), 第3次免疫后为( 94.50±52.84); ISA206 组第2次免疫后为(7.59±5.61), 第3次免疫后为( 25.60±16.92) ; IMS1312组第2次免疫后为(9.41±8.86), 第3次免疫后为( 28.92±12.98)。福氏佐剂组第2次免疫后特异性抗体滴度分别为ISA206 组的6.9和IMS1312组的5.6倍(F=81.06,P<0.01),第3次免疫后分别为ISA206 组的3.7和IMS1312组的3.3倍(F=13.29,P<0.01)。IFAT检测结果显示,经PbCP-2.9免疫的鼠血清与Pb ANKA株虫体表面抗原有阳性反应。 结论 PbCP-2.9基因在毕赤酵母中高效表达,重组抗原免疫原性强,其免疫血清能识别伯氏疟原虫天然抗原。

关键词: 伯氏疟原虫, 红内期, 融合抗原, 基因表达, 免疫原性

Abstract: Objective To produce an erythrocytic stage chimeric protein of Plasmodium berghei in Pichia pastoris and evaluate its immunogenicity. Methods The DNA sequences of AMA1(Ⅲ) and MSP1-19 from P. berghei homologous to the corresponding sequences of P. falciparum chimeric antigen 2.9 (PfCP-2.9) were fused to generate a chimeric gene,designated as PbCP-2.9. The resulting gene was redesigned using Pichia preferential coden usage and expressed in P. pastoris in the secreted form. The recombinant protein was purified by Ni-NTA affinity chromatography. Three groups each with 10 BALB/c mice were immunized subcutaneously with 20 μg of purified PbCP-2.9 antigen formulated in Freund’s adjuvant,Montanide ISA720 and Montanide IMS 1 312,respectively. Three control groups each with 10 mice received only adjuvants emulsified with PBS. All the mice received three immunizations at 2-week intervals with the same dose of antigen. Serum samples were collected at pre-immunization and one week after each immunization,and were analyzed for specific antibodies by ELISA and reaction with natural P. berghei proteins by IFAT. Results The PbCP-2.9 antigen with Mr 26 400 was successfully expressed in P. pastoris in secreted form. The recombinant protein can be recognized by the serum against blood stage parasites of P. berghei. High antibody responses were detected in all three PbCP-2.9-immune groups of mice by ELISA. However,mice immunized with PbCP-2.9 antigen in Freund’s adjuvant produced higher antibody titers than those with PbCP-2.9 antigen in Montanide ISA 206 and Montanide IMS 1312 adjuvants. The mean antibody titer in Freund’s adjuvant was 6.9-fold higher than in Montanide ISA 206 adjuvant and 5.6-fold higher than in Montanide IMS 1312 adjuvant after the second immunization (F=81.06,P<0.01). In addition,after the third immunization the mean antibody titer in Freund’s adjuvant was 3.7-fold higher than in Montanide ISA 206 adjuvant and 3.3-fold higher than in Montanide IMS 1312 adjuvant(F=13.29,P<0.01). The results from IFAT assay demonstrated that the immune sera recognized the surface proteins of P. berghei parasites. Conclusion The codenoptimized PbCP-2.9 gene has been constructed and expressed in P. pastoris. The chimeric antigen is highly immunogenic in mice and the immune sera can interact with natural proteins of P. berghei parasite.

Key words: Plasmodium berghei, Erythrocytic stage, Chimeric protein, Gene expreesion, Immunogenicity